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Valproate in Adjuvant Glioblastoma
Treatment
TO THE EDITOR: We are a group of clinicians and researchers
who have been studying the effect of sodium valproate (VPA) in
glioblastoma (GBM) since 2010. The study recently published in
Journal of Clinical Oncology by Happold et al1 pooled a number of
trial data sets to study a variety of interventions for glioblastoma
in which patients had taken anticonvulsants, including VPA. The
study concluded that VPA showed no beneﬁt on survival.
The motivation for the publication may be to dissuade cli-
nicians from using VPA in the absence of a randomized prospective
phase III trial that shows evidence of progression-free or overall
survival beneﬁt. However, the analysis may prematurely discourage
other groups from studying the interaction between VPA and
chemoradiotherapy as well as clinical outcomes with older drug
therapies.
This type of analysis typically suffers from bias because the
included trials were not equipped to answer the question of whether
VPA improves survival in GBM. Without identiﬁcation and control
of confounders, the signiﬁcance of the ﬁndings is compromised.
An example of a biased GBM study that led to potentially poor
practice is the recommendation to avoid VPA as an anticonvulsant
around the time of surgery based on reports of increased incidence
of bleeding. However, sicker patients with larger or more aggressive
tumors were more likely to have received VPA because of their
increased likelihood of having seizures. A large tumor cavity itself,
Table 1. Previous Literature That Examined VPA
First
Author
Included
Here
Cohort Size
HR (95% CI)
Deﬁnition
Notes
VPA
Positive
VPA
Negative VPA Negative VPA Positive
Felix4 No 22 22 0.31 (0.14 to 0.7) To 2006 2007 onward Multiple childhood tumors
No VPA 10-15 mg/kg/day as prophylactic
anticonvulsant (routinely)
No TMZ
Sometimes RT
No 16 15 0.42 (0.16 to 0.97) To 2006 2007 onward As above but brainstem tumors only
No VPA 10-15 mg/kg/day as prophylactic
anticonvulsant (routinely)
Felix5 No 13 6 0.6 (0.37 to 0.98) To 2006 2007 onward DIPG
No VPA 10-15 mg/kg/day as prophylactic
anticonvulsant (routinely)
No TMZ
Conformal RT
Cohort split on time period
Barker6 No 29 374 0.67 (0.27 to 1.07) Five other AEDs Phenytoin
Levetiracetam
Carbamazepine
Phenobarbital
VPA during RT
Dose unknown
GBM with seizures
RT
TMZ use and nonuse
Controlled confounders: RTOG RPS class,
concurrent TMZ, seizure history
Barker6 Yes 12 122 0.54 (0.09 to 1.17) Five other AEDs VPA during RT GBM with seizures
Phenytoin Levetiracetam
Carbamazepine
Phenobarbital
Dose unknown TMZ 1 RT
Kerkhof7 Yes 108 57 0.63 (0.43 to 0.92) No VPA or VPA, 3 months
with or without LEV and
other therapies
VPA . 3 months
Maintenance dose of 1,000 mg
Raised but usually , 2,000 mg
for ongoing seizures
Primary and recurrent GBM with seizures
TMZ 1 RT for primary
TMZ 1 chemotherapy for recurrent
Controlled confounders: age, resection
extent, and MGMT status
Obendorfer8 No 43 125 Survival data only No AED (n 5 88) or EI-AED
(n 5 43)
600-1,500 mg VPA (n 5 32) or
other non-EI-AED (n 5 13).
GBM
Sometimes with LEV
Chemotherapy 1 RT
Weller9 Yes 97 277 0.67 (0.53 to 0.9) No AED VPA only GBM
Dose unknown TMZ only
MGMT recorded but not controlled for
No 97 252 0.39 (0.24 to 0.63) EI-AED (four agents) and
other comparisons
VPA only
Dose unknown
GBM
TMZ 1 RT
MGMT recorded but not controlled for
Guthrie10 No 24 138 Cox-Mantel log-rank test No AED VPA GBM
EI-AEDs Dose unknown Chemotherapy 1 RT Controlled
confounders: age, KPS, resection extent,
location
Jaeckle11 No Compare EI-AED v none N/A N/A GBM
Controlled confounders: age, sex, function,
resection extent, steroid use
(n 5 620)
2% non-EI-AEDs
Abbreviations: AED, antiepileptic drug; DIPG, diffuse intrinsic pontine glioma; EI-AED, enzyme-inducing antiepileptic drug; GBM, glioblastoma multiforme; HR, hazard
ratio; KPS, Karnofsky performance status; LEV, levetiracetam; MGMT, O6-methylguanine-DNA methyltransferase; N/A, not available; RPS, recursive partitioning
analysis; RT, radiotherapy; RTOG, Radiation Therapy Oncology Group; TMZ, temozolomide; VPA, valproate
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irrespective of therapy, predisposes to bleeding. More data do not
remove bias, even if prospectively collected.
In addition, the dose and duration of VPA is neither re-
ported nor controlled for. Dose-response curves for the initial
effect can be quite different when used for a new applicationwhen
repurposing drugs. Our in vitro experimental studies on estab-
lished cell lines and primary human glioblastoma cells clearly
showed an interaction between VPA and chemoradiotherapy2,3
but only at the upper end of recommended doses for seizure
prevention. VPA dose does not directly relate to CSF concen-
tration in humans, and studies using subtherapeutic doses are of
limited clinical relevance.
From reported results (Table 1), three studies that considered
patients with GBM treated with temozolomide, and reported
hazard ratios were used in a meta-analysis. Some are cited by
Happold et al.1 The studies are not without issue. The analysis is
retrospective, and deﬁnitions for positive VPA use vary (data
source was an included factor). Like Happold et al, dose and
protocol were not always reported. Unlike other antiepileptic
drugs,6,9,10 VPA consistently had a small, but detectable beneﬁt
(Fig 1), not dissimilar to Table A2 in Happold et al.
The deﬁnition of VPA positive is critical to avoid obscuring
or even eliminating observed beneﬁcial effects (if any) of VPA,
especially if mild. The obscuring effect of misallocation was
simulated based on reported Kaplan-Meier curves.12 From 138
patients taking VPA, increasing numbers were randomly reas-
signed to the 24 VPA-positive patients to simulate inclusion of
other antiepileptic drugs. From a baseline hazard ratio of 0.9,
which indicated beneﬁt, the hazard ratio decreased to 0 (no
beneﬁt) when 32 patients had been reassigned.
We would consider that by controlling for protocol, the
types of patients recruited and reasons for taking VPA is crit-
ical to analysis. The debate around the use of VPA cannot be
resolved by further retrospective studies. There are clearly
difﬁculties in investigating therapies in this uncommon disease
(, 1% of cancer diagnoses) and in a heterogeneous patient
group.12,13 However, a prospective analysis is not onerous be-
cause it simply requires the use and dose of VPA to be reported
in forthcoming prospective studies with a placebo group and
matched for confounders such as promoter status, histology,
stage, age of patient, and comorbidities. Although less ideal than
a randomized controlled trial, it certainly would provide better
evidence than the work to date.
In conclusion, we suggest that the clinical effectiveness of VPA
in adjuvant glioblastoma treatment has yet to be deﬁnitively in-
vestigated. A research bias exists toward new molecules over new
applications of old drugs, many with proven anticancer efﬁcacy and
safety.14 Given our limited progress in improving GBM survival, it
would be regrettable to eliminate these by holding them to the
higher standard of demonstrating efﬁcacy in the face of un-
controlled confounders.
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Fig 1. Forest plot that shows a meta-analysis of three studies of VPA use (speciﬁcally with the exclusion of enzyme-inducing antiepileptic drugs) in glioblastoma
multiforme with concurrent temozolomide and radiotherapy. HR, hazard ratio; VPA1/2, taking/not taking valproate.
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